Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised VEF AB (publ) in connection with the listing of the company’s ordinary shares on Nasdaq Stockholm’s Main Market
Mandate

Vinge has advised VEF AB (publ) in connection with the listing of the company’s ordinary shares on Nasdaq Stockholm’s Main Market

June 03, 2022 Capital Markets and Public M&A Corporate Tax

Vinge has advised VEF AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s Main Market. The prospectus was published on 30 May 2022 and the trading on Nasdaq Stockholm commenced on 1 June 2022.

VEF is an investment company that invests in growth stage private fintech companies. VEF focuses on scale emerging markets and invests across all areas of financial services inclusive of payments, credit, mobile money and wealth advisors.

Vinge’s team has primarily consisted of Jesper Schönbeck, Joel Wahlberg, Emma Brolund, Anna Svensson and Johannes Akyol (Capital Markets and Public M&A) and Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025